Status:

TERMINATED

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Lead Sponsor:

Melbourne Health

Collaborating Sponsors:

Sanofi

National Heart Foundation, Australia

Conditions:

Deep Vein Thrombosis

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (...

Eligibility Criteria

Inclusion

  • Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient history or ECG evidence.

Exclusion

  • Patients with a past history of DVT or PE.
  • Patients with a history of clotting disorders
  • Patients with active malignancies
  • Patients requiring full heparinisation during and after the procedure.
  • Chronic atrial flutter and atrial fibrillation ablation

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2011

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00232271

Start Date

August 1 2005

End Date

February 1 2011

Last Update

May 30 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Royal Melbourne hospital

Melbourne, Victoria, Australia, 3050